CIK 0001652130
- Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 364785571
- Phone
- +1 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 4 Open-market sale EVP, Chief Technical Officer sold 607 shares at $13.78 ($8,364)
- 4 Grant or award VP, Chief Accounting Officer acquired 17,250 shares (grant or award)
- 4 Open-market sale President and CEO sold 34,146 shares at $9.21 ($314,485)
- 4 Open-market sale EVP, Chief Scientific Officer sold 8,508 shares at $9.21 ($78,359)
- 4 Open-market sale EVP, General Counsel sold 10,397 shares at $9.21 ($95,756)
- 4 Open-market buy Director bought 150,000 shares at $9.35 ($1,402,500)
- 4 Open-market sale EVP, Chief Medical Officer sold 11,903 shares at $9.21 ($109,627)
- 4 Open-market sale EVP, Chief Technical Officer sold 9,515 shares at $9.21 ($87,633)
- 4 Open-market sale EVP, Chief Financial Officer sold 6,379 shares at $9.21 ($58,751)
- 4 Open-market sale VP, Chief Accounting Officer sold 2,989 shares at $9.21 ($27,529)
- 4 Planned sale President and CEO sold 88,146 shares at an average $9.49 ($836,384)
- 4 Open-market sale EVP, Chief Scientific Officer sold 31 shares at $17.38 ($539)
- 4 Open-market sale VP, Chief Accounting Officer sold 1,871 shares at $17.38 ($32,518)
- 4 Open-market buy Director bought 100,000 shares at $10.03 ($1,003,000)
- 4 Open-market sale EVP, Chief Financial Officer sold 7,462 shares at $14.02 ($104,617)
- 4 Open-market sale EVP, Chief Technical Officer sold 1,022 shares at $9.82 ($10,036)
- 4 Open-market sale VP, Chief Accounting Officer sold 2,503 shares at $9.95 ($24,905)
- 4 Planned sale Director sold 3,094 shares at an average $9.40 ($29,068)
- 4 Grant or award Director acquired 8,000 shares (grant or award)
- 4 Grant or award Director acquired 8,000 shares (grant or award)
Page 2 of 18 · 353 filings